Chris Sweeney
advisory
oncology
ANZUP Cancer Trials Group Ltd
Australia
Biography
Dr. Christopher J Sweeney received his medical degree from the University of Adelaide, South Australia in 1993 and went on to complete a fellowship in Haematology/Oncology at Indiana University Medical Center. He became a faculty member at Indiana University and was appointed Associate Director for Clinical Research for the Simon Cancer Center. In 2008 he was granted appointments at the Royal Adelaide Hospital and University of Adelaide and then joined the Lank Center for Genitourinary Oncology at the Dana Farber Cancer Institute with an appointment at Harvard Medical School. He is a member of the American Society of Clinical Oncology, the Eastern Cooperative Oncology Group, and the American Association for Cancer Research. His primary research interest is biomarker drug discovery and development. His academic focus is management of genitourinary malignancies. He has served on the Editorial Board for ASCO’s “Journal of Clinical Oncology” and the Program and Cancer Education Committees of the American Society of Clinical Oncology and ASCO GU. He receives peer reviewed funding from the National Institutes of Health and the Department of Defence.
Research Interest
Dr. Christopher J Sweeney received his medical degree from the University of Adelaide, South Australia in 1993 and went on to complete a fellowship in Haematology/Oncology at Indiana University Medical Center. He became a faculty member at Indiana University and was appointed Associate Director for Clinical Research for the Simon Cancer Center. In 2008 he was granted appointments at the Royal Adelaide Hospital and University of Adelaide and then joined the Lank Center for Genitourinary Oncology at the Dana Farber Cancer Institute with an appointment at Harvard Medical School. He is a member of the American Society of Clinical Oncology, the Eastern Cooperative Oncology Group, and the American Association for Cancer Research. His primary research interest is biomarker drug discovery and development. His academic focus is management of genitourinary malignancies. He has served on the Editorial Board for ASCO’s “Journal of Clinical Oncology” and the Program and Cancer Education Committees of the American Society of Clinical Oncology and ASCO GU. He receives peer reviewed funding from the National Institutes of Health and the Department of Defence.
